Author

D. Rossi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. J. Arribas· 4 shared F. Bertoni· 4 shared L. Cascione· 4 shared A. Stathis· 3 shared C. Tarantelli· 3 shared E. Cannas· 3 shared E. Gaudio· 3 shared E. Zucca· 3 shared

Activity by Year

2018-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. J. Arribas

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

F. Spriano, L. Cascione, J. Sgrignani, N. Bendik, S. Napoli, G. Sartori, E. Cannas, T. Gong, A. J. Arribas, M. Pizzi, D. Rossi, D. F. Robbiani, A. Cavalli, F. Bertoni

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

A. J. Arribas, E. Gaudio, S. Napoli, C. J. Herbaux, C. Tarantelli, R. Bordone Pittau, L. Cascione, N. Munz, L. Aresu, J. Sgrignani, A. Rinaldi, I. Kwee, D. Rossi, A. Cavalli, E. Zucca, , F. Bertoni

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

bioRxiv · Nov 14, 2023 · PreprintCancer Biology

Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

C. Tarantelli, D. Wald, N. Munz, F. Spriano, A. Bruscaggin, E. Cannas, L. Cascione, E. Gaudio, A. J. Arribas, S. Manjappa, G. Golino, L. Scalise, E. Zucca, A. Stathis, P. H. Van Berkel, , F. Bertoni

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

bioRxiv · Aug 17, 2023 · PreprintCancer Biology

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

A. J. Arribas, S. Napoli, L. Cascione, L. Barnabei, G. Sartori, E. Cannas, E. Gaudio, C. Tarantelli, A. A. Mensah, F. Spriano, A. Zucchetto, F. M. Rossi, A. Rinaldi, M. Castro de Moura, S. Jovic, , F. Bertoni

This study identifies ERBB4-mediated signaling as a mechanism of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms and shows that targeting ERBB signaling can restore sensitivity.

bioRxiv · Jan 1, 2023Cancer Biology

Nanoscale investigation in 3D scaffolds of cell-material interactions for tissue-engineering

D. Iandolo, F. A. Pennacchio, V. Mollo, D. Rossi, D. Dannhauser, B. Cui, R. M. Owens, F. Santoro

The paper investigates cell-material interactions in 3D scaffolds using SEM/FIB to better understand cellular adhesion and guide tissue-engineering design.

bioRxiv · Aug 2, 2018Bioengineering